Cis-diamminedichloroplatinum (II)
Authors:
- 1 June 1977
- journal article
- review article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 86 (6) , 803-812
Abstract
Cis-diamminedichloroplatinum (II) (DDP) leads the series of platinum coordination complexes, a new class of cytotoxic agents. The antitumor and toxic effects of this drug are discussed. It has displayed encouraging results in testicular tumors. The drug's therapeutic effectiveness has also been recognized in a variety of other solid tumors, particularly ovarian, bladder, and head and neck malignancies. Gastrointestinal, renal, audiologic, and relatively minor hematologic toxicities may be encountered, but promising methods have been developed to increase the therapeutic index of DDP.Keywords
This publication has 70 references indexed in Scilit:
- Phase II evaluation of bleomycin.A Southwest Oncology Group studyCancer, 1976
- Combination chemotherapy with adriamycin andcis-diamminedichloroplatinum in patients with neoplastic diseasesCancer, 1976
- Management of Ovarian CarcinomaNew England Journal of Medicine, 1976
- Chemotherapy of germ cell tumors of the testis. I. Induction of remissions with vinblastine, actinomycin D, and bleomycinCancer, 1976
- Combination Chemotherapy with cis-Diamminedichloroplatinum (II) and Bleomycin in Tumors of the Head and NeckOncology, 1975
- Bleomycin, an Antitumor AntibioticAnnals of Internal Medicine, 1972
- The Inhibition of Growth or Cell Division in Escherichia coli by Different Ionic Species of Platinum(IV) ComplexesJournal of Biological Chemistry, 1967
- Platinum-Induced Filamentous Growth in Escherichia coliJournal of Bacteriology, 1967
- Chemotherapy of metastatic testis cancer:Results in 154 patientsCancer, 1966
- CLINICAL STUDIES OF ACTINOMYCIN DAnnals of the New York Academy of Sciences, 1960